Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

SIMPLE SUMMARY: Cyclin-dependent kinase (CDK) 4/6 inhibitors, in combination with endocrine therapies, are now the standard of care for patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Despite the effectiveness of CDK4/6 inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Kamal, Katuwal, Nar Bahadur, Park, Nahee, Hur, Jin, Cho, Young Bin, Kim, Seung Ki, Lee, Seung Ah, Kim, Isaac, Lee, Seung-Ryeol, Moon, Yong Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750394/
https://www.ncbi.nlm.nih.gov/pubmed/35008374
http://dx.doi.org/10.3390/cancers14010210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750394/
https://www.ncbi.nlm.nih.gov/pubmed/35008374
http://dx.doi.org/10.3390/cancers14010210

Ejemplares similares